GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (OTCPK:SPHRF) » Definitions » Price-to-Free-Cash-Flow

Starpharma Holdings (Starpharma Holdings) Price-to-Free-Cash-Flow : N/A (As of Jun. 07, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Starpharma Holdings Price-to-Free-Cash-Flow?

As of today (2024-06-07), Starpharma Holdings's share price is $0.0783. Starpharma Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01. Hence, Starpharma Holdings's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Starpharma Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:

SPHRF's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.425
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Starpharma Holdings's Free Cash Flow per Share for the six months ended in Dec. 2023 was $0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.01.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -6.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -4.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 2.10% per year.

During the past 13 years, Starpharma Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was 39.00% per year. The lowest was -29.80% per year. And the median was -5.40% per year.


Starpharma Holdings Price-to-Free-Cash-Flow Historical Data

The historical data trend for Starpharma Holdings's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings Price-to-Free-Cash-Flow Chart

Starpharma Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Starpharma Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Starpharma Holdings's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Starpharma Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Starpharma Holdings's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's Price-to-Free-Cash-Flow falls into.



Starpharma Holdings Price-to-Free-Cash-Flow Calculation

Starpharma Holdings's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.0783/-0.011
=N/A

Starpharma Holdings's Share Price of today is $0.0783.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Starpharma Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Starpharma Holdings  (OTCPK:SPHRF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Starpharma Holdings Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Starpharma Holdings (Starpharma Holdings) Business Description

Traded in Other Exchanges
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.

Starpharma Holdings (Starpharma Holdings) Headlines

From GuruFocus

Starpharma's SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

By Business Wire Business Wire 09-14-2020

Starpharma to present at OTCQX Virtual Investor Conference

By PRNewswire PRNewswire 04-11-2018

Starpharma creates slow release soluble DEP remdesivir nanoparticle

By Business Wire Business Wire 09-01-2020

Starpharma SPL7013 Nasal Spray for COVID-19 – Development Update

By Business Wire Business Wire 08-25-2020

Starpharma Presentation Now Available for On-Demand Viewing

By PRNewswire PRNewswire 04-17-2018

Starpharma's SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

By Business Wire Business Wire 09-14-2020

Starpharma signs new DEP� agreement with MSD

By PRNewswire PRNewswire 08-10-2022

Starpharma signs DEP� ADC Research Agreement with MSD

By PRNewswire PRNewswire 02-12-2021